Solventum Corporation $SOLV Shares Sold by Equity Investment Corp

Equity Investment Corp reduced its position in Solventum Corporation (NYSE:SOLV) by 1.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 867,554 shares of the company’s stock after selling 14,466 shares during the quarter. Equity Investment Corp owned approximately 0.51% of Solventum worth $76,475,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in SOLV. Diamond Hill Capital Management LLC Investment Advisor bought a new position in Solventum during the second quarter valued at approximately $150,066,000. Bank of New York Mellon Corp purchased a new position in shares of Solventum during the second quarter worth approximately $61,460,000. Assenagon Asset Management S.A. lifted its holdings in shares of Solventum by 16,656.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 482,930 shares of the company’s stock worth $42,570,000 after acquiring an additional 480,048 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of Solventum by 6,103.8% in the 2nd quarter. Squarepoint Ops LLC now owns 243,128 shares of the company’s stock valued at $18,757,000 after purchasing an additional 239,209 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Solventum by 44.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 774,683 shares of the company’s stock valued at $50,576,000 after purchasing an additional 236,659 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Mizuho set a $113.00 target price on shares of Solventum in a research report on Thursday, August 6th. Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research note on Saturday. UBS Group upped their price target on shares of Solventum from $95.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Solventum in a research note on Thursday, October 8th. Finally, Wedbush lifted their price target on Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Nine equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $90.27.

Solventum Trading Down 0.4%

NYSE:SOLV opened at $90.09 on Wednesday. The firm has a market capitalization of $15.29 billion, a P/E ratio of 12.83, a P/E/G ratio of 1.29 and a beta of 0.69. The company has a quick ratio of 0.72, a current ratio of 1.03 and a debt-to-equity ratio of 0.99. The company has a fifty day moving average of $87.71 and a 200 day moving average of $78.80. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $94.16.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, November 5th. The company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.11. The firm had revenue of $1.95 billion for the quarter, compared to analysts’ expectations of $1.93 billion. Solventum had a net margin of 1.91% and a return on equity of 25.03%. The company’s revenue for the quarter was down 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.50 earnings per share. On average, research analysts predict that Solventum Corporation will post 7.26 earnings per share for the current year.

About Solventum

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.